Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized trial of topical AT-004 1% in acne vulgaris
2025-521510-25-00Phase 2Completed
- Sponsor
- Arctic Therapeutics
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acne vulgaris comparing AT-004 1% topical with Matched placebo topical (2 arms). Primary endpoints: Safety adverse events, Local skin reactions and 3 more. Started Nov 2025; status: completed.
02
Drugs
Blontress
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2025-521510-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521510-25-00.